相关实验视频

Updated: Jul 14, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

外周免疫和炎症标记作为预测者新辅助免疫疗法响应在头部和部状细胞癌的预测

Wendi Li¹, Lin Xiao¹, Haiyang Li²

¹State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Annals of medicine

|June 23, 2025

概括

新的血液标记物,包括CD28阴性PD-1-阳性CD8+ T细胞和白细胞计数,可以预测头癌免疫治疗反应. 这有助于个性化治疗接受免疫检查点抑制剂的患者.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物标志物发现发现

背景情况:

头部和部状细胞癌 (HNSCC) 具有有限的免疫检查点抑制剂 (ICI) 反应率的挑战.
血基生物标志物对于预测HNSCC患者免疫疗法的疗效至关重要,特别是在新辅助环境中.

研究的目的:

确定外周血液免疫和炎症标志物,预测HNSCC患者对新辅助ICI治疗的反应.
评估这些生物标志物的预测准确性,单独和组合,使用接收器运行特征 (ROC) 曲线分析.

主要方法:

从接受新辅助ICI治疗的52名新诊断的HNSCC患者收集了外周血液样本.
通过使用多个染色面板的流细胞测量评估免疫细胞表型.
以后回顾分析了例行血液计数,生化标志物和细胞因子水平.

主要成果:

六种免疫标记物,包括各种CD8+ T细胞子集 (例如PD-1dim/CD8+,CD28-PD-1+/CD8+ T细胞),在非响应者中升高.
炎症标志物如白细胞 (WBC) 计数,中性粒细胞和C反应蛋白 (CRP) 与反应相关.
CD28-PD-1+/CD8+ T细胞和WBC的组合模型实现了0.82的AUC,高于0.59的组合阳性得分 (CPS) AUC.

结论:

外周免疫标记物,特别是CD28-PD-1+/CD8+T细胞,以及炎症标记物,如白细胞计数,在预测HNSCC中ICI反应方面显示出有前途.
这些发现支持基于易于获得的血液生物标志物为HNSCC患者开发个性化免疫疗法策略.

关键词:

头部和部状细胞癌 (HNSCC)免疫检查点抑制剂 (ICI)新辅助免疫疗法新辅助免疫疗法周围血液周围血液

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.